by the end of 2023 we shouldhave the following: • PTX-100 phase 2 trial • Omnicar in the clinic with the new thermofisher technology and hopefully some interim data • Initial Cellpryme deal? • PTX-200 readout
by the end of 2023 we could have the following: • PTX-100 registrational (fast track approval) trial *very likely* • Multiple cellpryme deals • Further Omnicar deals such as partnerships much like our one with MD Anderson • Joint venture with Thermofisher to develop Omnicar through clinical trials (purely my speculation). If Thermo were looking to acquire prescient, I think they may dip their toes in the water with a JV before committing to a full takeover.
If the Should haves come to fruition, I don’t think a 250M market cap would be unreasonable, that is a share price of approx $0.31
However if the Could haves come to fruition, then you would have to atleast double that I would have thought……. Atleast
PTX Price at posting:
9.2¢ Sentiment: Buy Disclosure: Held
